Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
Can raloxifene be combined with stronger osteoporosis agents in patients who are on raloxifene for a breast cancer diagnosis?
Related Questions
What is your approach to management of patients with recurrent nephrolithiasis and osteoporosis who are receiving teriparatide?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
How should we interpret DXA scans in patients with Ankylosing Spondylitis who have ankylosis of the spine?
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
For those treating osteoarthritis with LDRT, is there any concern of adverse effects or decreased efficacy in patients with osteoporosis?
Is elevated bone specific alkaline phosphatase an absolute contraindication to teriparatide?
How would you approach a patient with osteoporosis who remains at risk for osteoporotic fracture and who had an atypical femur fracture on denosumab?
Do you use bone turnover markers to assess medical adherence in patients treated for osteoporosis?
When transitioning from anabolic agent to denosumab, do you stop teriparatide 1 day prior to transition and romosozumab 1 month prior to transition?
Is there a PTH elevation above which you would be hesitant to use an anabolic agent in a patient with osteoporosis and CKD stage 4 or 5?
